Science Explorer Back to mapMap

Most cited papers from Concert Pharmaceuticals (United States)

What are the most cited papers from Concert Pharmaceuticals (United States)?

The most cited paper from Concert Pharmaceuticals (United States) is "Deuterium in Drug Discovery and Development" (Scott L. Harbeson, Roger D. Tung, 2011), with 145 citations. Next come "Sex-Dependent Shared and Nonshared Genetic Architecture Across Mood and Psychotic Disorders" (142) and "Burden of Illness in Alopecia Areata: A Cross-Sectional Online Survey Study" (110).

Showing 50 of 58 papers. Every paper with more than 7 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Deuterium in Drug Discovery and Development Scott L. Harbeson, Roger D. Tung · Annual reports in medicinal chemistry Book chapter 2011 145
2 Sex-Dependent Shared and Nonshared Genetic Architecture Across Mood and Psychotic Disorders Gabriëlla A.M. Blokland et al. · Biological Psychiatry Open access961 authors 23 Mar 2021 142
3 Burden of Illness in Alopecia Areata: A Cross-Sectional Online Survey Study Natasha Atanaskova Mesinkovska, Brett King, Paradi Mirmirani et al. · Journal of Investigative Dermatology Symposium Proceedings Conference paperOpen access 21 Oct 2020 110
4 Deuterium Medicinal Chemistry Comes of Age Roger D. Tung · Future Medicinal Chemistry Open access Apr 2016 98
5 Development of the alopecia areata scale for clinical use: Results of an academic–industry collaborative effort Brett King et al. · Journal of the American Academy of Dermatology Open access 30 Aug 2021 90
6 Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areata Brett King, Natasha Atanaskova Mesinkovska, Paradi Mirmirani et al. · Journal of the American Academy of Dermatology Open access 29 Mar 2022 85
7 Altering Metabolic Profiles of Drugs by Precision Deuteration 2: Discovery of a Deuterated Analog of Ivacaftor with Differentiated Pharmacokinetics for Clinical Development Scott L. Harbeson, Adam J. Morgan, Julie F. Liu et al. · Journal of Pharmacology and Experimental Therapeutics Open access 13 Jun 2017 85
8 Failed trials for central nervous system disorders do not necessarily invalidate preclinical models and drug targets Anton Bespalov, Thomas Steckler, Bruce M. Altevogt et al. · Nature Reviews Drug Discovery Open access 17 Jun 2016 85
9 Clinical Genetics Lacks Standard Definitions and Protocols for the Collection and Use of Diversity Measures Alice B. Popejoy, Kristy Crooks, Stephanie Malia Fullerton et al. · The American Journal of Human Genetics Open access 5 Jun 2020 81
10 Pharmacokinetics, Safety, and Tolerability of Teduglutide, a Glucagon‐Like Peptide‐2 (GLP‐2) Analog, Following Multiple Ascending Subcutaneous Administrations in Healthy Subjects Jean‐Francois Marier, Martin Béliveau, Samer Mouksassi et al. · The Journal of Clinical Pharmacology 30 Oct 2008 78
11 Measuring health-related quality of life in chronic obstructive pulmonary disease: properties of the EQ-5D-5L and PROMIS-43 short form Fang‐Ju Lin, Alan Simon Pickard, Jerry A. Krishnan et al. · BMC Medical Research Methodology Open access 16 Jun 2014 74
12 The Friends of Cancer Research Real‐World Data Collaboration Pilot 2.0: Methodological Recommendations from Oncology Case Studies Donna R. R Rivera et al. · Clinical Pharmacology & Therapeutics Open access 20 Oct 2021 59
13 Altering Metabolic Profiles of Drugs by Precision Deuteration: Reducing Mechanism-Based Inhibition of CYP2D6 by Paroxetine Vinita Uttamsingh, Richard Gallegos, Julie F. Liu et al. · Journal of Pharmacology and Experimental Therapeutics 6 May 2015 59
14 Racial Differences in Patient-Reported Symptoms and Adherence to Adjuvant Endocrine Therapy Among Women With Early-Stage, Hormone Receptor–Positive Breast Cancer Xin Yang Hu, Mark Stephen Walker, Edward J. Stepanski et al. · JAMA Network Open Open access 10 Aug 2022 50
15 Cytochrome P450 3A4 and CYP3A5-Catalyzed Bioactivation of Lapatinib Joanna K Towles, Rebecca N Clark, Michelle D. Wahlin et al. · Drug Metabolism and Disposition Open access 23 Jul 2016 45
16 A Decade of Deuteration in Medicinal Chemistry Julie F. Liu, Scott L. Harbeson, Christopher L. Brummel et al. · Annual reports in medicinal chemistry Book chapter 2017 39
17 OnabotulinumtoxinA Injection for Poststroke Upper‐Limb Spasticity: Guidance for Early Injectors From a Delphi Panel Process David Martin Simpson, Atul T. Patel, Abraham Alfaro et al. · PM&R Open access 23 Jun 2016 39
18 Enhancing e-communities with agent-based systems S Case, Nader Azarmi, Marcus Thint et al. · Computer Jul 2001 39
19 Clinical Pathway for Suicide Risk Screening in Adult Primary Care Settings: Special Recommendations Lynsay A. Ayer, Lisa M. Horowitz, Lisa J. Colpe et al. · Journal of the Academy of Consultation-Liaison Psychiatry Open access 23 May 2022 37
20 The contribution of agonist and antagonist activities of α4β2* nAChR ligands to smoking cessation efficacy: a quantitative analysis of literature data Hans Rollema, Raymond S Hurst · Psychopharmacology 6 Jul 2018 37
21 Deuterium Medicinal Chemistry: A New Approach to Drug Discovery and Development Scott L. Harbeson, Roger D. Tung May 2014 32
22 The direct and indirect health care costs associated with pulmonary arterial hypertension among commercially insured patients in the United States Adesuwa S. Ogbomo, Yuen Tsang, Rajesh Mallampati et al. · Journal of Managed Care & Specialty Pharmacy Open access Jun 2022 31
23 A First‐in‐Patient, Multicenter, Double‐Blind, 2‐Arm, Placebo‐Controlled, Randomized Safety and Tolerability Study of a Novel Oral Drug Candidate, CTP‐499, in Chronic Kidney Disease LuAnn Sabounjian, Philip B. Graham, Lijun Wu et al. · Clinical Pharmacology in Drug Development Open access Dec 2015 27
24 Real‐world Overall Survival Using Oncology Electronic Health Record Data: Friends of Cancer Research Pilot Laura Lasiter, Olga Tymejczyk, Elizabeth S. Garrett-Mayer et al. · Clinical Pharmacology & Therapeutics Open access 19 Oct 2021 24
25 Telehealth and Medicare Type 2 Diabetes Care Outcomes Brigham Walker, Charles Stoecker, Yixue Shao et al. · Medical Care Open access 9 Mar 2023 23
26 Bridging e-business and added trust: keys to e-business growth Hsunwei Hsiung, S. Scheurich, Frank E. Ferrante · IT Professional 2001 22
27 Real-world evidence provides clinical insights into tissue-agnostic therapeutic approvals George W. Sledge, Takayuki Yoshino, Joanne Xiu et al. · Nature Communications Open access 18 Mar 2025 21
28 COVID-19 and Routine Childhood and Adolescent Immunizations: Evidence from Louisiana Medicaid Brigham Walker, Andrew C Anderson, Charles Stoecker et al. · Vaccine Open access 24 Dec 2021 21
29 Temozolomide analogs with improved brain/plasma ratios – Exploring the possibility of enhancing the therapeutic index of temozolomide Roopa Rai et al. · Bioorganic & Medicinal Chemistry Letters 24 Aug 2016 19
30 Dual Therapeutic Effects of C-10068, a Dextromethorphan Derivative, Against Post-Traumatic Nonconvulsive Seizures and Neuroinflammation in a Rat Model of Penetrating Ballistic-Like Brain Injury Xi‐Chun May Lu, Deborah A. Shear, Philip B. Graham et al. · Journal of Neurotrauma Open access 20 Mar 2015 19
31 Real-World Treatment Patterns and Effectiveness Outcomes in Patients with Early-Stage Triple-Negative Breast Cancer Amin Haiderali, Whitney Rhodes, Santosh Gautam et al. · Future Oncology Open access 6 Jul 2021 17
32 Randomized trial of proactive rapid genetic counseling versus usual care for newly diagnosed breast cancer patients Marc D. Schwartz, Beth N. Peshkin, Claudine J. Isaacs et al. · Breast Cancer Research and Treatment Open access 2 Apr 2018 17
33 Design and synthesis of deuterated boceprevir analogs with enhanced pharmacokinetic properties Adam J. Morgan, Sophia Nguyen, Vinita Uttamsingh et al. · Journal of Labelled Compounds and Radiopharmaceuticals Jul 2011 17
34 Real-World Treatment Patterns and Outcomes in PD-L1-Positive Non-Small Cell Lung Cancer Xinke Zhang, Richard W DeClue, Lisa Herms et al. · Immunotherapy Open access 4 Aug 2021 16
35 Advancing the genetic counseling profession through research: Identification of priorities by the National Society of Genetic Counselors research task force Leigha Senter, Jehannine Austin, Meghan E. Carey et al. · Journal of Genetic Counseling Open access 23 Sep 2020 16
36 Real-world use of bevacizumab-awwb, a bevacizumab biosimilar, in US patients with metastatic colorectal cancer Whitney Rhodes, Richard W DeClue, Neil A. Accortt et al. · Future Oncology Open access 26 Oct 2021 15
37 Characterization of Clinical Symptoms by Race Among Women With Early-Stage, Hormone Receptor–Positive Breast Cancer Before Starting Chemotherapy Xin Yang Hu, Puneet Kaur Chehal, Cameron M. Kaplan et al. · JAMA Network Open Open access Jun 2021 15
38 Clinical and economic impact of recurrence in early-stage non-small-cell lung cancer following complete resection Howard West, Xiaohan Hu, Diana Romana Chirovsky et al. · Future Oncology Open access 23 May 2023 14
39 Quantitative analyses of CTP-499 and five major metabolites by core-structure analysis Xiaonan Tang, Gary W. Bridson, Jing Ke et al. · Journal of Chromatography B 28 May 2014 14
40 Building an infrastructure to enable delivery of genomic medicine Gillian W. Hooker · American Journal of Medical Genetics Part C Seminars in Medical Genetics Open access 7 Jan 2021 13
41 Predictors of contralateral prophylactic mastectomy in genetically high risk newly diagnosed breast cancer patients Mara Tynan, Beth N. Peshkin, Claudine J. Isaacs et al. · Breast Cancer Research and Treatment Open access 2020 13
42 Real-world outcomes among patients with metastatic colorectal cancer treated first line with a bevacizumab biosimilar (bevacizumab-awwb) Ran Jin, Adesuwa S. Ogbomo, Neil A. Accortt et al. · Therapeutic Advances in Medical Oncology Open access 2023 12
43 Real-World Outcomes in Metastatic HR+/HER2-, HER2+ and Triple Negative Breast Cancer after Start of First-Line Therapy Richard W DeClue, Maxine D. Fisher, Kyna Gooden et al. · Future Oncology Open access Apr 2023 12
44 Evaluation of Real-World Tumor Response Derived From Electronic Health Record Data Sources: A Feasibility Analysis in Patients With Metastatic Non–Small Cell Lung Cancer Treated With Chemotherapy Brittany Avin McKelvey et al. · JCO Clinical Cancer Informatics Open access Aug 2024 11
45 Healthcare Resource Utilization and Cost Among Patients Treated for Early-Stage Triple-Negative Breast Cancer Amin Haiderali, Whitney Rhodes, Santosh Gautam et al. · Future Oncology Open access 13 Jul 2021 11
46 Performance Testing for IP Services and Systems Frank Huebner, Kathleen S. Meier-Hellstern, Paul Kevin Reeser · Lecture notes in computer science Conference paper 2001 11
47 Payer reimbursement practices and incentives for improving interpretation of germline genetic testing Patricia A. Deverka, Janis Geary, Charles Mathews et al. · Journal of Law and the Biosciences Open access Jul 2023 10
48 Adaptation of couples living with a high risk of breast/ovarian cancer and the association with risk-reducing surgery Rachel Shapira, Erin Turbitt, Lori Hamby Erby et al. · Familial Cancer Open access 5 Dec 2017 10
49 Emulations of oncology trials using real-world data: a systematic literature review Jennifer R. Rider et al. · American Journal of Epidemiology Review 6 Sep 2024 9
50 Identification and Characterization of Oxymetazoline Glucuronidation in Human Liver Microsomes: Evidence for the Involvement of UGT1A9 Mukesh K. Mahajan, Vinita Uttamsingh, Liang-Shang L. Gan et al. · Journal of Pharmaceutical Sciences Open access 29 Jul 2010 9

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.